Publications by authors named "Sven Wind"

Claim this Profile
A
Absorption, Metabolism, Distribution and Excretion (ADME) and Absolute Bioavailability Assessment of Zongertinib in Healthy Male Volunteers.
Rolf Grempler, David Joseph, Guanfa Gan, Adam M Auclair, Renger G Tiessen, Sven Wind

Clin Drug Investig· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.
Stefan Wölke, Behbood Sadrolhefazi, Habib Esmaeili, Sven Wind, Simone M Blattner

Mol Pharm· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.
Hélène Pereira, Stefan Wölke, Behbood Sadrolhefazi, Habib Esmaeili, Sven Wind

Mol Pharm· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers.
Xiaofan Tian, Habib Esmaeili, David Minich, Friedeborg Seitz, Philipp M Roessner, Sven Wind

Pharmacotherapy· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
Michael Desch, Christina Schlecker, Kathrin Hohl, Karl-Heinz Liesenfeld, Tom Chan, Sven Wind

J Clin Psychopharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Madelon C Vonk, Alfredo Guillén-Del-Castillo, Michael Kreuter, Mandy Avis, Kristell Marzin, Sven Wind

Eur J Drug Metab Pharmacokinet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Michael Desch, Glen Wunderlich, Markus Goettel, Sophia Goetz, Karl-Heinz Liesenfeld, Sven Wind

Eur J Drug Metab Pharmacokinet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Sven Wind, Ulrike Schmid, Matthias Freiwald, Kristell Marzin, Ralf Lotz

Clin Pharmacokinet· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
Luca Richeldi, Sophie Fletcher, Huzaifa Adamali, Nazia Chaudhuri, Sabrina Wiebe, Sven Wind

Eur Respir J· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Holger Rosenbrock, Michael Desch, Oliver Kleiner, Cornelia Dorner-Ciossek, Bernhard Schmid, Sven Wind

Clin Transl Sci· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Viktoria Moschetti, Christina Schlecker, Sven Wind, Sophia Goetz, Holger Schmitt

Clin Drug Investig· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.
Viktoria Moschetti, Michael Desch, Sophia Goetz, Karl-Heinz Liesenfeld, Holger Rosenbrock, Sven Wind

Eur J Drug Metab Pharmacokinet· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
Sabrina Wiebe, David Schnell, Raimund Külzer, Dietmar Gansser, Anne Weber, Sven Wind

Eur J Drug Metab Pharmacokinet· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Sven Wind, David Schnell, Thomas Ebner, Matthias Freiwald, Peter Stopfer

Clin Pharmacokinet· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Michael S Gordon, Gregory M Springett, Yungpo Bernard Su, Mahmoud Ould-Kaci, Sven Wind

Future Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
Katharina Gunzer, Florence Joly, Jean-Marc Ferrero, Joseph Gligorov, Helene de Mont-Serrat, Sven Wind

Springerplus· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
David A Reardon, Louis B Nabors, Warren P Mason, James R Perry, William Shapiro, Sven Wind

Neuro Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
David Schnell, Susanne Buschke, Holger Fuchs, Dietmar Gansser, Rainer-Georg Goeldner, Sven Wind

Cancer Chemother Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Matthias Freiwald, Ulrike Schmid, Angele Fleury, Sven Wind, Peter Stopfer

Cancer Chemother Pharmacol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Sven Wind, Thomas Giessmann, Arvid Jungnik, Tobias Brand, Kristell Marzin

Clin Drug Investig· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Sven Wind, Marion Schmid, Julia Erhardt, Rainer-Georg Goeldner, Peter Stopfer

Clin Pharmacokinet· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Martin Schuler, Ahmad Awada, Philipp Harter, Jean Luc Canon, Kurt Possinger, Sven Wind

Breast Cancer Res Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Nancy U Lin, Eric P Winer, Duncan Wheatley, Lisa A Carey, Stephen Houston, Sven Wind

Breast Cancer Res Treat· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition.
Sven Wind, Knut Beuerlein, Melanie E Armitage, Ashraf Taye, Arun H S Kumar

Hypertension· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant.
Sabine Heumüller, Sven Wind, Eduardo Barbosa-Sicard, Harald H H W Schmidt, Rudi Busse

Hypertension· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis